



Connecticut Society of Eye Physicians

Scientific CME Regional Meeting January 12th Virtual & January 13th Live, 2023

- World Class Faculty
- Dynamic & Relevant Lecture Topics
- Innovation
- Wellness and Balance



EDWARD LIM, MD
MODERATOR

Over 500 Ophthalmologists attending



VINCENT DELUISE, M.D.
MODERATOR

Physicians Agenda and Registration



Orbiting the Eye


www.connecticutsocietyofeyephysicians.com

THURSDAY, JANUARY 12, 2023

VIRTUAL SESSION SCHEDULE

5:30 pm Welcome Remarks & Sponsor Introductions
– Ed Lim, MD & Vincent deLuise, MD – Moderators

5:44 pm Product Theatre - REGENERON




5:45 pm Management of Malignant Glaucoma – Arsham Sheybani, MD

Objectives: 1. To recognize conditions that can lead to malignant glaucoma 2. To understand the physiology of malignant glaucoma 3. To discuss the rationale for the treatment of malignant glaucoma




6:15 pm Neuro-ophthalmology – Andrew G. Lee, MD

Objectives: 1. To define life threatening etiologies of diplopia 2. To list distinctive and differentiating features of dangerous double vision 3. To list the differential diagnosis for acute bilateral ophthalmoplegia in the ER 4. To describe the distinctive neuroimaging findings for the above entities




6:45 pm Management of Keratoconus and Crosslinking – William B. Trattler, MD

Objectives: 1. The course will educate attendees on keys to diagnose keratoconus at an earlier stage, including topography interpretation. Once diagnosed, the course will focus on crosslinking, including postoperative management. 2. Attendees are expected to learn tools & techniques for identifying patients with normal slit lamp exams who have keratoconus. Attendees will learn the positive impact CXL is expected to have, as well as postoperative management. 3. The course will help attendees evaluate patients with keratoconus, either before or after crosslinking, to determine if they are stable or progressing.



7:15 pm Update on Corneal Transplantation – Yuri McKee, MD

Objectives: 1. To review the advances in corneal transplantation surgery 2. To review the benefits and drawbacks of each transplant technique



7:45 pm Local vs. Systemic Therapy for Uveitis – Nisha Acharya, MD

Objectives: 1. To understand the risks and benefits of local vs systemic therapy for uveitis, including ocular and systemic risks. 2. To understand the treatment options for uveitic macular edema.

8:15 pm Product Theater – VABYSMO (faricimab-svoa) injection, the first dual pathway-inhibiting therapy designed to target Ang-2 and VEGF-A for the treatment of patients with nAMD or DME

Genentech



Dr. David R. Lally received a medical degree from Jefferson Medical College in Philadelphia, PA. He completed his ophthalmology residency at the Wills Eye Hospital in Philadelphia, and then went on to a fellowship in Vitreoretinal Diseases and Surgery at Tufts/New England Eye Center and Ophthalmic Consultants of Boston. Dr. Lally is board certified and an active member of the American Society of Retinal Specialists (ASRS) with the Fellow of the American Society of Retinal Specialists (FASRS) award designation. He is also an active member of the American Academy of Ophthalmology (AAO). He is an attending surgeon at Baystate Medical Center and an Assistant Professor of the Department of Surgery at the University of Massachusetts Medical School-Baystate.

9:00 pm Adjournment

The Connecticut Society of Eye Physicians designates this educational activity for a maximum of 2.5 AMA PRA Category I Credit(s)TM.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Connecticut Society of Eye Physicians is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.

FRIDAY, JANUARY 13, 2023 LIVE SESSION SCHEDULE

7:50 am Registration Martha Howard, MD - Moderator

8:15 am Business Meeting

8:45 am Friday the 13th Cases - Yale Residents




Perspectives of Resident and Attending Physicians on Common Ethical Dilemmas in Research – Michael Flitsis, MD

Progressive Bilateral Vision Loss in a 52-Year-Old Man – Thuzar Thein, MD

A Case of a Cerebral Red Herring – Kendrick Wang, MD




Objectives: Residents will present cases, review treatments & outcomes

9:15 am Break with Vendors in Wagon Room



9:45 am Herbst Lecture – Future Treatments for Early and Intermediate Age-related Macular Degeneration


– Joan W. Miller, MD *Objectives:* 1. To review our understanding of the pathophysiology of AMD based on molecular biology and genomics 2. To explore the strategies needed to advance our understanding of the pathophysiology of AMD, and ultimately to develop new treatments for early and intermediate AMD



10:45 am The Future is 3D: OCT Imaging Beyond the RNFL – Teresa C. Chen , MD

Objectives: 1. To understand the background and science behind the discovery of 3D OCT technology 2. To understand the limitations of current commercially available OCT software 3. Understand current 3D imaging research, which will address those limitations

11:45 am Lunch with Vendors - Glass Room



12:30 pm New Innovative Directions in Ophthalmic Telemedicine, AI, & Remote Monitoring – James C. Tsai, MD

Objectives: 1. To gain greater understanding of future of tele-ophthalmology 2. To learn about tele-retina screening programs 3. To understand advances in AI & remote patient monitoring

1:00 pm Friday the 13th Cases - New York Residents

Not Your Usual Winter Coats – Antonios Dimopoulos, MD

Acute Macular Neuroretinopathy after COVID-19 Infection – Laura Barna, MD

Objectives: New York Residents will present cases, review treatments & outcomes



1:30 pm Freaky Crawlies, Black Cats, Full Moons, Moldy Habitats....Do They Give You the Creeps?

– Kelsey Kaman, MD; Connecticut Asthma and Allergy Center

Objectives: 1. To be able to identify common aeroallergen triggers for allergic conjunctivitis as well as evidence-based avoidance and treatment measures 2. To be able to identify common contact allergens contributing to ocular dermatitis

2:00 pm Coffee/Tea Break with Vendors



2:15 pm * Adolescent and Young Adult Cannabis Use – Omar Shah, MD; Psychiatry, Boston Children's Hospital

Objectives: 1. What is cannabis/marijuana? 2. What are the important receptors and neurotransmitters associated with use? 3. What are the neurodevelopmental changes from

3:00 pm Door Prizes – Certificates

* Special Certificate will be given for state required CME in the category of: Cultural Competency

The Connecticut Society of Eye Physicians designates this educational afternoon activity for a maximum of 4.0 AMA PRA Category I Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The Connecticut Society of Eye Physicians is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.

Speaker Bios

NISHA ACHARA, MD

Dr. Nisha Acharya is the Elizabeth C. Proctor Distinguished Professor of Ophthalmology, Epidemiology & Biostatistics at the University of California San Francisco and Director of the Uveitis and Ocular Inflammatory Disease Service at the F.I. Proctor Foundation. She is also the Associate Director of the Proctor Foundation and Vice Chair for Faculty Development and Mentorship in the Department of Ophthalmology. Dr. Acharya is a clinician-scientist with a clinical focus on uveitis and ocular inflammatory diseases. She has an NIH-funded research program that focuses on the design and implementation of international clinical trials and outcomes research on ocular inflammatory diseases. She is the current president of the American Uveitis Society. Dr. Acharya has mentored numerous medical students, residents, fellows and faculty over the years, and has been recognized with a Dean's Award for Mentorship.

TERESA C. CHEN, MD

Dr. Chen is an Associate Professor of Ophthalmology at the Harvard Medical School, she completed her fellowship in 1998 at Massachusetts Eye & Ear Infirmary, Boston, MA and over the last two decades has published over 200 publications. Currently she is a full-time ophthalmologist and surgeon at the Massachusetts Eye and Ear Infirmary (MEEI), Harvard Medical School's Department of Ophthalmology, Glaucoma Service.

Since 2001, Dr. Chen has collaborated with Massachusetts General Hospital (MGH) researchers, who developed three-dimensional (3D) spectral domain OCT (SDOCT) and swept source OCT (SSOCT), the two most commonly used 3D imaging technologies in the clinics and at academic teaching institutions.

Dr. Chen's current research goals include improving 3D imaging tools worldwide, in order to better diagnose glaucoma, to better monitor structural disease progression, to have better clinical trial endpoints, to improve telemedicine potential, to improve artificial intelligence (AI) capabilities, and to improve our understanding of glaucoma.

ANDREW G. LEE, MD

Dr. Lee is the Herb and Jean Lyman Centennial Chair in Ophthalmology and is the Founding Chairman of the Blanton Eye Institute, Department of Ophthalmology at Houston Methodist Hospital in Houston, Texas and is Professor of Ophthalmology, Neurology, and Neurosurgery at Weill Cornell Medicine. He is adjunct professor of Ophthalmology at Baylor College of Medicine; Texas A and M College of Medicine; University of Iowa and the University of Buffalo; and Clinical Professor at the University of Texas Medical Branch in Galveston, Texas and the UT MD Anderson Cancer Center.

Dr. Lee has been an AAO member for over 25 years and has served in numerous leadership roles at the AAO including member of the OKAP Committee, Chair of the AAO Task Force on Aging and later, AAO Committee on Aging. He has received AAO the AAO Achievement Award, Senior Achievement Award, Secretariat Award (2X), and Lifetime Achievement Award and he volunteers with the Minorities in Ophthalmology Mentors (MOM) program. He has been on the AAO Annual Program Meeting Committee and the AAO-NANOS Committee and is the NANOS representative and Treasurer for the Association of University Professors in Ophthalmology (AUPO) Fellowship Compliance Committee (FCC). He is a past President and Current Chairman of the Board of North American Neuro-ophthalmology Society (NANOS) and has board membership experience at the medical organization and lay levels including Board of Trustees, Houston Symphony, Treasurer and Board of Houston Neurological Society (HNS), Treasurer and Board of Houston Ophthalmological Society (HOS). Dr. Lee has been the invited speaker at over 300 national and international medical meetings; has written over 500 peer reviewed publications and 14 full textbooks; and has given 15 named lectures. He lives in Houston, Texas with his wife, two daughters, and two cats.

KELSEY KAMAN, MD

Kelsey Kaman, MD BSN is a graduate of University of Connecticut School of Nursing and subsequently School of Medicine. She completed her pediatric residency at Baystate Medical Center and completed her fellowship in Allergy and Immunology at Yale University in 2021. She then joined Connecticut Asthma and Allergy Center in Connecticut. With grant funding from the American College of Allergy, Asthma and Immunology, Dr. Kaman's research is focused on better understanding and addressing disparities that low socio-economic status, Black and Hispanic food allergic children face in our local communities.

YURI MCKEE, MD

Dr. McKee specializes in advanced corneal transplant techniques, premium cataract surgery, anterior segment reconstruction, glaucoma surgery, LASIK and refractive surgery. He has authored peer reviewed articles on corneal transplantation and repair of dislocated intraocular lenses, and numerous chapters in textbooks. He served as Executive Editor for five textbooks on advanced ophthalmic surgery. Dr McKee has also lectured around the world at international meetings regarding these topics.

Prior to his training in Ophthalmology Dr. McKee served as an active duty US Air Force Flight surgeon where he attained the rank of Major. During this time, he was the medical director of the Aerospace Medicine Clinic and the course director of Top Knife II USAF Flight Surgeon High Performance Aircraft Course at Luke AFB, Arizona. Dr McKee was stationed in Okinawa, Japan for four years where he served in a combat- ready F-15 Eagle squadron. Dr. McKee was deployed twice in support of Operation Enduring Freedom where he logged numerous combat flight hours in both air superiority and combat search and rescue missions. His commitment to service was recognized with numerous military medals and awards, including a Command Flight Surgeon of the Year distinction.

Dr. McKee is a native of Minnesota. He is married with two children. He enjoys skiing, scuba diving, and international travel. Most of all Dr McKee values time spent with his family.

JOAN W. MILLER, MD

Joan W. Miller, MD, is the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School (HMS), as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital and Ophthalmologist-in-Chief at Brigham and Women's Hospital. A graduate of Massachusetts Institute of Technology, Dr. Miller earned her MD from HMS and completed her ophthalmology residency and vitreoretinal fellowship at Mass Eye and Ear. In 2002, Dr. Miller became the first female physician to achieve the rank of Professor of Ophthalmology at HMS, and in 2003, the first woman to serve as Chair of the Department of Ophthalmology. She is also the first woman appointed as Chief of Ophthalmology at both Mass Eye and Ear and Mass General Hospital.

An internationally recognized expert on retinal disorders, Dr. Miller and her colleagues at Mass Eye and Ear/HMS pioneered the development of

verteporfin photodynamic therapy (Visudyne®), the first pharmacologic therapy for age-related macular degeneration (AMD). The group also identified the key role of vascular endothelial growth factor (VEGF) in ocular neovascularization, leading to the development of anti-VEGF therapies now administered to millions of people with sight-threatening retinal diseases annually around the world. Dr. Miller's current research investigations focus on the pathogenesis of AMD, including genomics, metabolomics, imaging, and functional measures; strategies for early intervention in AMD; and neuroprotective therapies for retinal disease.

Her scholarly contributions include 390 original research investigations, reviews, book chapters, and editorials. Dr. Miller serves on the editorial board for the journals *Ophthalmology* and *Ophthalmology Retina*, and has served as an editor for several textbooks, including the recently published 4th edition (Springer) of Albert and Jakobiec's *Principles and Practices of Ophthalmology*. Dr. Miller is a member of the National Academy of Medicine, the Academia Ophthalmologica Internationalis, the American Ophthalmological Society, and the Dowling Society, as well as a Gold Fellow of the Association for Research in Vision and Ophthalmology (ARVO). Among her numerous honors, Dr. Miller was a co-recipient of the 2014 António Champalimaud Vision Award, the highest distinction in ophthalmology and visual science. In 2015, Dr. Miller became the first woman to receive the Mildred Weisenfeld Award for Excellence in Ophthalmology from ARVO; in 2018, she became the first woman awarded the Charles L. Schepens Award from American Academy of Ophthalmology (AAO). Additionally, Dr. Miller was awarded the 2018 Lucien Howe Medal from the American Ophthalmological Society and the 2018 Gertrude D. Pyron Award from the American Society of Retinal Specialists.

OMAR ALI SHAH, MD

Dr. Omar Shah is an addiction medicine fellow at Harvard Medical School/Boston Children's Hospital. He is a Ruth Fox Scholar of ASAM (American Society of Addiction Medicine) and a recipient of the AAP (American Academy of Addiction Psychiatry) John Renner Award. He currently serves as the Vice Chair of the APA (American Psychiatric Association) Leadership Fellowship. He is also the current awardee of the (AADPRT) American Association of Directors of Psychiatric Residency Training's Nyapati Rao and Francis Lu Fellowship. He completed his adult psychiatry training at the Delaware Psychiatry Residency Program and his child and adolescent psychiatry training at the Geisel School of Medicine at Dartmouth College. Dr. Shah is interested in working with patients with complex psychosocial burdens, and families with substance use.

ARSHAM SHEYBANI, MD

Dr. Arsham Sheybani completed his medical degree with honors (AOA) at Washington University School of Medicine in St. Louis. He then completed his residency in Ophthalmology at Washington University in St. Louis and was selected to remain on faculty as Chief Resident. During that year, Dr. Sheybani was responsible for ophthalmologic trauma and emergencies as well as all adult inpatient ophthalmology consultations at Barnes Jewish Hospital. He was the primary surgical teacher for the beginning residents and implemented a didactic system that is still used at Washington University. He then completed a fellowship with Ike Ahmed in Glaucoma and Advanced Anterior Segment Surgery in Toronto, Canada. He subsequently returned to Washington University School of Medicine as faculty in the Department of Ophthalmology and Visual Sciences where he serves as Residency Program Director. He is currently involved in device design aiming to make glaucoma surgery safer. He is also developing biomarkers for the diagnosis and monitoring of Primary Open Angle and Pseudoexfoliation Glaucoma. He is an avid surgical teacher, winning the resident selected faculty teaching award early in his career and he was honored by the American Glaucoma Society as the Surgery Day Lecturer. His true passion remains in maintaining one of the highest volume surgical glaucoma and anterior segment surgery fellowships in the country serving as the fellowship director.

WILLIAM B. TRATTLER, MD

Dr. William Trattler received his bachelor's degree with honors from Dartmouth College and his Doctorate of Medicine degree from University of Miami School of Medicine, where he graduated in 1992 with Distinction in Research. He completed his ophthalmology residency at University of Pennsylvania, Scheie Eye Institute and spent a year in training in Cornea and Refractive Surgery at the University of Texas Southwestern Medical Center in Dallas. During his Corneal Fellowship,

Dr. Trattler performs a wide variety of refractive surgeries, including PRK, LASIK, LASEK, ICL, and Refractive Lens Exchange. He is a high volume refractive cataract surgeon. He is a leader in the field of corneal collagen crosslinking for keratoconus, Pellucid, and post-LASIK ectasia. Dr. Trattler also has a strong focus in Dry Eye, MGD, and treatments for presbyopia.

Dr. Trattler has participated in over 70 clinical trials, including both device and pharmaceutical clinical trials. William Trattler, MD serves as Chairman of the Board for the American-European Congress of Ophthalmic Surgery (AECOS) through December 2022. Dr. Trattler, has served on the Executive Board of the International Society of Refractive Surgery (ISRS) from 2011 through 2019 as well as the Refractive Surgery Alliance (RSA) from 2015 to present. Dr. Trattler has served as the Program Director of the Advanced Refractive Congress (ARC) from 2015 to 2019. Dr. Trattler is the Co-Program Director for AECOS Deer Valley, and is on the program committee for Hawaiian Eye, OSN NY, Modern Optometry Live, and CedarsAspens Annual Conference.

Dr. Trattler has written hundreds of articles (both peer and non-peer reviewed) focused on crosslinking for keratoconus, cataract surgery, multifocal IOLs, LASIK, laser vision correction, dry eye and MGD. Dr. Trattler has also given more than 400 presentations at Regional, National and International Conferences.

Dr. Trattler is board certified by the American Board of Ophthalmology and has written many articles and abstracts, including as co-author of *Microbiology Made Ridiculously Simple*, a textbook used by medical, nursing and veterinary students throughout the world. Dr. Trattler is also Co-author of *Review of Ophthalmology*, an Ophthalmology Boards review book that is used by residents to prepare for their written boards.

JAMES C. TSAI, MD, MBA, FACS

Dr. Tsai serves as President of New York Eye and Ear Infirmary of Mount Sinai (NYEE), the nation's first and longest operating specialty hospital, as well as System Chair of the Department of Ophthalmology at the Icahn School of Medicine at Mount Sinai (ISMMS) and Mount Sinai Health System. In addition, he is the inaugural Delafield-Rodgers Professor of Ophthalmology at ISMMS. Prior to joining Mount Sinai, Tsai served as the inaugural Robert R. Young Professor and Chair of the Department of Ophthalmology and Visual Science at Yale University School of Medicine and Chief of Ophthalmology at Yale-New Haven Hospital. Prior to his Yale faculty appointment, he directed the glaucoma division at the Edward S. Harkness Eye Institute, Columbia University College of Physicians and Surgeons. Author of more than 100 peer-reviewed scientific publications and over 80 additional articles, chapters, and textbooks, including the *Oxford American Handbook of Ophthalmology* and *Medical Management of Glaucoma* (4 editions), Tsai has served as editorial board member for 9 medical journals and manuscript reviewer for over 100 additional scientific journals.

FINANCIAL DISCLOSURES FOR CME PROGRAM

Speaker	Financial Interest Received
Nisha Acharya, MD	None
Teresa C. Chen, MD	None
Andrew G. Lee, MD	National Football League, NASA, US Dept. Justice – <i>Consultant</i> ; Harizen – <i>Advisory</i>
Kelsey Kaman, MD	None
Yuri McKee, MD	None
Joan W. Miller, MD	Kal Vista Pharmaceuticals, Sunovion, Heidelberg Engineering – <i>Consultant</i> ; Aptinyx, Inc. – <i>Board of Directors, Stock Options</i> ; ONL Therapeutics – <i>Consultant, Stock Options, Patent/IP</i> ; Valeant Pharmaceuticals/Mass Eye and Ear – <i>Royalties, Patents/IP</i> ; Ciendias Bio – <i>Equity</i> ; Drusolv Therapeutics – <i>Patents/IP</i>
Omar Ali Shah, MD	None
Arsham Sheybani, MD	AbbVie, Alcon, Santen, Nova Eye, Glaukos – <i>Consultant</i>
William B. Trattler, MD	Allergan, Bausch & Lomb, sun Pharmaceuticals, J&J, Alcon, Lensar, RxSight, Glaukos, Oculus, Avellino Labs, Azura Ophthalmics, Sight Sciences, Zeiss – <i>Consultant, Speaker</i>
James C. Tsai, MD	Eyenovia, Nektar, Shire - <i>Consultant</i>

CONNECTICUT SOCIETY OF EYE PHYSICIANS PHYSICIANS CME EVALUATION FORM January 12, 2023 Virtual Educational Program - fax 860-496-1830

Name _____ Email _____

Please evaluate the following topics on a scale of 1 to 4 with the following values:

1 - poor 2 - satisfactory 3 - good 4 - excellent

Circle One

- | | |
|------------------------------|---------|
| 1. SUBJECT MATTER OF MEETING | 1 2 3 4 |
| 2. FACILITIES | 1 2 3 4 |
| 3. AUDIOVISUAL | 1 2 3 4 |
| 4. SPEAKERS | 1 2 3 4 |

Malignant Glaucoma and UGH Syndrome – Arsham Sheybani, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Neuro-ophthalmology – Andrew G. Lee, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Management of Keratoconus and Crosslinking – William Trattler, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Update on Corneal Transplantation – Yuri McKee, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Local vs. Systemic Therapy for Uveitis – Nisha Acharya, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Competency Questions

Local vs. Systemic Therapy for Uveitis – *Nisha Acharya, MD*

Question 1. Repeated short-acting corticosteroid injections can be adequate treatment for chronic uveitic conditions such as multifocal choroiditis. ☐ True ☐ False:

Question 2. What percentage of eyes with uveitic macular edema will have a recurrence after resolution of macular edema?

- a. 25%
- b. 30%
- c. 40%
- d. 60%

Neuro-ophthalmology – *Andrew G. Lee, MD*

Question 1. Which of the following is the most likely etiology for diplopia in a 45 year old man with an acute, painful (“worst headache of their life”), pupil involved third nerve palsy?

- a. Posterior communicating artery aneurysm
- b. Giant cell arteritis
- c. Pituitary apoplexy
- d. Arterial dissection

Question 2. Which of the following is the most likely etiology for diplopia in a 25 year old pregnant woman with an associated bitemporal hemianopsia?

- a. Posterior communicating artery aneurysm
- b. Giant cell arteritis
- c. Pituitary apoplexy
- d. Arterial dissection

Question 3. Which of the following is the most likely etiology for diplopia in a 25 year old alcoholic woman with altered mental status in the ER?

- a. Giant cell arteritis
- b. Arterial dissection
- c. Wernicke encephalopathy
- d. Myasthenia gravis

Question 4. Which of the following is the most likely etiology for recurrent, painless, variable, and intermittent, pupil-sparing ophthalmoplegia and ptosis in a 45 year old man?

- a. Giant cell arteritis
- b. Arterial dissection
- c. Wernicke encephalopathy
- d. Myasthenia gravis

Update on Corneal Transplantation – *Yuri McKee, MD*

Question 1. Which allogenic corneal transplant technique has the lowest risk of graft rejection?

- a. Penetrating Keratoplasty
- b. Descemets Stripping Automated Endothelial Keratoplasty (DSAEK)
- c. Descemets Membrane Endothelial Keratoplasty (DMEK)
- d. The immune rejection rates between these techniques are statistically equal.

Question 2. Contraindications to DMEK include:

- a. Fuchs Dystrophy
- b. Pseudophakic Bullous Keratopathy
- c. A small inferior iridotomy
- d. Aphakia

Management of Keratoconus and Crosslinking – *William Trattler, MD*

Question 1. Crosslinking is a potential treatment for all of the following except

- a. Keratoconus with a thin cornea (300 microns)
- b. Pellucid Marginal Degeneration
- c. Progressive Keratoconus in a 65 year old male
- d. 42 year old Post-LASIK patient who reports difficulty with reading

Question 2: A 27 year old patient with severe keratoconus is found to have a very thin corneas - approximately 250 microns. He has been wearing scleral lenses and is very happy with his vision. However - he is progressing. What are the next steps to try to prevent further progression?

Which of the following is the best answer:

- a. Place Intacs in both corneas
- b. Perform optimized CXL with shortened UV exposure time based on the Hafezi nomogram
- c. Continue with scleral lenses and do not recommend CXL as the cornea is too thin
- d. Recommend corneal transplants in both eyes - since the cornea is too thin for CXL

**CONNECTICUT SOCIETY OF EYE PHYSICIANS
PHYSICIANS CME EVALUATION FORM
January 13, 2023 Live Educational Program - fax 860-496-1830**

Name _____ Email _____

Please evaluate the following topics on a scale of 1 to 4 with the following values:

1 - poor 2 - satisfactory 3 - good 4 - excellent

Circle One

- | | |
|------------------------------|---------|
| 1. SUBJECT MATTER OF MEETING | 1 2 3 4 |
| 2. FACILITIES | 1 2 3 4 |
| 3. AUDIOVISUAL | 1 2 3 4 |
| 4. SPEAKERS | 1 2 3 4 |

New Innovative Directions in Ophthalmic Telemedicine, AI, & Remote Monitoring – James C. Tsai, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Herbst Lecture – Future Treatments for Early and Intermediate Age-related Macular Degeneration – Joan W. Miller, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

The Future is 3D: OCT Imaging Beyond the RNFL – Teresa C. Chen, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

Freaky Crawlies, Black Cats, Full Moons, Moldy Habitats....Do They Give You the Creeps? – Kelsey Kaman, MD

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

*** Adolescent and Young Adult Cannabis Use – Omar Shah, MD**

- | | |
|---|--------------|
| Degree to which objectives were met | 1 2 3 4 |
| Did speaker disclose financial interests in any product or company? | ___Yes ___No |
| Was the presentation fair and balanced? | ___Yes ___No |

**January 13, 2023 Live Educational Program - fax 860-496-1830
Competency Questions**

The Future is 3D: OCT Imaging Beyond the RNFL – Teresa C. Chen, MD

Question 1. As glaucoma worsens, which retinal layer is harder for the OCT machine to automatically segment?

The anterior RNFL (retinal nerve fiber layer)

- a. The anterior RNFL (retinal nerve fiber layer)
- b. The posterior RNFL (retinal nerve fiber layer)
- c. The outer plexiform layer
- d. The retinal pigment epithelium

Question 2. Compared to SDOCT (spectral domain OCT), advantages of SSOC (swept source OCT) include all but the following?

- a. Better visualization of the choroidal vasculature
- b. Faster scan speeds
- c. Greater depth penetration
- d. Shorter wavelength

Herbst Lecture – Future Treatments for Early and Intermediate Age-related Macular Degeneration – Joan W. Miller, MD

Question 1. Complement genes have been implicated in the pathogenesis of AMD and therefore represent ideal treatment targets.

☐ True ☐ False:

Question 2. Neuroprotection may be useful in preventing geographic atrophy. Select the approaches being investigated:

- a. Reduction of oxidative stress
- b. Prevention of apoptosis and necroptosis
- c. Modulation of the visual cycle
- d. Anti-VEGF treatment



Connecticut Society of Eye Physicians

Annual Education Program

Virtual January 12 & Live January 13, 2023

The Aqua Turf Club

556 Mulberry Street, Plantsville, CT

CSEP Physician Program Registration Form

(ophthalmologists only)

Fax to 860-496-1830 or Email debbieosborn36@yahoo.com

Please make the following reservations:

#_____ CSEP members at \$125.00 pre-registered (Virtual and/or Live), *After Jan. 1, 2023 \$155.00*

#_____ MA, RI, NY, NJ ophthalmologists who are members of their state society or AAO at \$125.00 pre-registered (Virtual and/or Live), *After January 1, 2023 \$155.00*

#_____ Non-CSEP ophthalmologists at \$200.00 pre-registered (Virtual and/or Live), *\$230.00 After January 1, 2023 \$220.00*

#_____ Residents (all states) - Complimentary

*Note: Per direction of the Executive Committee, attendance at CSEP sponsored educational physician meetings is limited to physicians, or out of state physicians who are members of their state society, and ophthalmology residents and fellows.

Name _____ Street _____

City _____ State _____ Zip _____

Email Address _____ Telephone _____

My check for \$ _____ is enclosed

Please mail this form with your payment to: CSEP, P.O. Box 854, Litchfield, CT 06759

FAX: 860-496-1830 with enclosed credit card form

You can scan this form and email with credit card information to debbieosborn36@yahoo.com

(for CSEP office use only)

Check # _____ Received: _____ Amount: \$ _____

EARLY BIRD REGISTRATION DEADLINE JANUARY 1, 2023

Virtual Program: The Connecticut Society of Eye Physicians designates this educational activity for a maximum of 2.5 AMA PRA Category I Credit(s)™.

Live Program: The Connecticut Society of Eye Physicians designates this educational afternoon activity for a maximum of 4.0 AMA PRA Category I Credit(s)™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Connecticut Society of Eye Physicians is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.



Connecticut Society of Eye Physicians

Virtual and/or Live Program January 12 & 13, 2023

Credit Card Payment Form

Fax to 860-496-1830 or Email debbieosborn36@yahoo.com

-----Visa ----- Mastercard ----- American Express

----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /----- /
(16 digit card number)

----- /----- /-----
(Expiration date)

----- /----- /-----
*3 digit # that appears on the back of the Visa/Mastercard

----- /----- /----- /-----
*4 digit # that appears on the front of the American Express

Name of Physician _____

Email Address _____

Cell Phone _____

\$ ----- Total amount charged

(Card holder's name)

(Card holder's signature)

(Card holder's address)

(Practice name)

(City - State)

*5 digit Zip code (required)

----- Email address

CSEP, 26 Sally Burr Road • P.O. Box 854 • Litchfield, CT 06759 • www.connecticutsocietyofeyephysicians.com

Please fill out completely! *These numbers are required.



26 Sally Burr Road
PO Box 854
Litchfield, CT 06759

www.connecticutsocietyofeyephysicians.com

SAVE THE DATE

FRIDAY, JUNE 9, 2023



The Aqua Turf Club • 556 Mulberry Street • Plantsville, CT